Aim This narrative review aims to describe established and emerging urinary biomarkers in
the diagnosis and surveillance of non-muscle invasive bladder cancer. It provides a …

Bladder cancer is the most common malignancy of the urinary tract. Cystoscopy represents
the gold standard in the diagnosis of suspicious bladder lesions. However, the procedure is …

Context During the past decade, several urinary biomarker tests (UBTs) for bladder cancer
have been developed and made commercially available. However, none of these is …

Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise
in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is …

Urine markers to detect bladder cancer have been the subject of research for decades. The
idea that urine—being in continuous contact with tumour tissue—should provide a vector of …

Bladder cancer is one of the most financially burdensome cancers globally, from its
diagnostic to its terminal stages. The impact it imposes on patients and the medical …

Aim: This is a narrative review with an aim to summarise and describe urinary biomarkers in
the surveillance of non-muscle-invasive bladder cancer (NMIBC). It provides a summary of …

Background State‐of‐art non‐invasive diagnosis processes for bladder cancer (BLCA)
harbour shortcomings such as low sensitivity and specificity, unable to distinguish between …

Bladder cancer (BC) is the 10th most frequent cancer in the world. The initial diagnosis and
surveillance of BC require a combination of invasive and non-invasive methods, which are …

MicroRNAs (miRNAs) can be secreted into body fluids and have thus been reported as a
new type of cancer biomarker. This study aimed to determine whether urinary miRNAs act as …